Samsung Biologics announces strategic agreement with Bristol Myers Squibb

Samsung Biologics has officially announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer medicine substance.

Bristol Myers Squibb and Samsung Biologics have been working together for a while to make a medicine for cancer. They’ve decided to work even more closely now. Samsung Biologics will make the medicine at their big factory in South Korea called Plant 4.

“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” said John Rim, President and CEO of Samsung Biologics. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”

Samsung Biologics

Related Posts

Leave a Comment